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Abstract  The efficiency and the viability of three hemoglobin screening programs were investi-
gated. They were offered on a voluntary basis to a Brazilian population and started with the
analysis of blood donors, pregnant women and students. The hemoglobin screening was done
through optional exams which included electrophoresis of hemoglobin and complementary
hematological tests. A total of 13,670 people were tested over a period of 39 months and a total of
644 individuals with hereditary hemoglobin disorders were detected – 4.7% of the samples ex-
amined. The programs showed satisfactory indicators of viability and efficiency, expressed by the
significative proportion of exams performed among the probands and their relatives.
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Resumo  Foram testadas a viabilidade e a eficiência de três programas de triagem de hemoglo-
binopatias. Os programas foram oferecidos voluntariamente a uma população brasileira e ini-
ciaram com o exame de doadores de sangue, gestantes e escolares dos ensinos fundamental e mé-
dio. A triagem das hemoglobinopatias foi realizada mediante exames opcionais, representados
pela eletroforese de hemoglobinas e exames complementares. Um total de 13.670 pessoas foram
investigadas em um período de 39 meses, diagnosticando-se 644 portadores de alterações heredi-
tárias da hemoglobina – 4,7% da amostra examinada. Os programas mostraram indicadores
satisfatórios de viabilidade e de eficiência, expressos pela proporção significativa de exames rea-
lizados entre os propósitos e os seus parentes.
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Introduction
Hemoglobinopathies, especially sickle cell syn-
dromes, hemoglobin C, and b thalassemia are
common in Brazil because of the population’s
ethnic composition (Salzano & Tondo, 1982;
Ramalho, 1986; Naoum et al., 1987). Although
the implementation of hemoglobinopathy pro-
grams in Latin America has been recommend-
ed by the World Health Organization (WHO,
1983), the Third World Academy of Science
(TWAS, 1986), and the Pan-American Health
Organization (OPS, 1987), systematic screen-
ing of heterozygotes for genetic counseling in
Brazil is still very limited and is only performed
in a few university centers. The WHO Commit-
tee for the Prevention and Control of Hemoglo-
binopathies has again recommended the im-
plementation of community hemoglobinopa-
thy programs in Latin America, especially in
Brazil (Penchaszadeh, 1993).
Still, the success of a community hemoglo-
binopathy program depends on the popula-
tion’s receptivity to such surveys. It is impor-
tant to evaluate the results, since receptivity
hinges on socioeconomic, psychological, and
cultural factors. Indeed, as Bowman (1991)
commented, population programs are often
conceived in a theoretical, idealized world. In
practice, however, they are carried out in the
very different real world.
The present study focused on the efficiency
of three voluntary hemoglobin screening pro-
grams developed in a Brazilian population,
starting with blood testing in pregnant women,
blood donors, and students.
Sampling and methods
The programs were developed in the State of
São Paulo, whose population has an apprecia-
ble number of African (hemoglobins S and C)
and Italian descendants ( b thalassemia). A to-
tal of 9,196 blood donors, 2,209 pregnant
women, and 2,074 students were invited for
screening at the State University of Campinas
(Unicamp) over a period of 39 months. Blood
donors and pregnant women were recruited at
the university hospital and students at public
schools in the community. Most of these indi-
viduals were of low socioeconomic status.
Screening for hemoglobinopathies was per-
formed by standard methods: complete blood
count, hemoglobin electrophoresis in cellulose
acetate-alkaline pH, red blood cell osmotic
fragility, confirmation of b -thalassemia trait by
increased Hb A2 fraction (Hb A2 quantification
by the usual elution method, after electrophore-
sis), confirmation of hemoglobin S by solubil-
ity tests, and confirmation of fetal hemoglo-
bin by the alkaline denaturation test (Rama-
lho, 1986). b thalassemia was not investigated
among blood donors, since this condition gen-
erally correlates with significant anemia. Cases
that could not be diagnosed by these standard
methods were submitted to specific tests, in-
cluding DNA analysis. Molecular analysis was
performed by DNA amplification (PCR) fol-
lowed by restriction enzyme digestion and sin-
gle-stranded conformational polymorphism
analysis (SSCP).
Individuals were asked to participate vol-
untarily in the programs. Parental permission
was required for high school students. Those
found to be hemoglobin trait carriers were
asked to bring their partners, parents, children
(including newborns), and other relatives for
investigation. All the above-mentioned tests
were performed on these individuals.
Prenatal fetal diagnosis was not offered to
high-risk couples, since Brazilian legislation
forbids therapeutic abortion in these cases. All
other laboratory tests, as well as medical treat-
ment and genetic counseling, when necessary,
were provided free of charge.
Individual and family interest in genetic
counseling was evaluated objectively based on
the percentage of screened heterozygotes who
brought their partners, children, or other rela-
tives for laboratory tests. They had received op-
tional and individualized genetic counseling
after evaluation by an interdisciplinary team
consisting of geneticists, psychologists, and so-
cial workers. Genetic counseling had been
completed with an identification card and ex-
planatory booklet about hemoglobin disorders
supplied to each subject.
Symptomatic individuals referred by physi-
cians in the community were also tested (n =
185). Parents, siblings, partners, and children
of positive hemoglobin disorder patients diag-
nosed in this group were invited for examina-
tion (n = 368). b -thalassemia trait was the main
clinical hypothesis, followed by sickle cell syn-
dromes.
Results
All blood donors and pregnant women, but on-
ly 54% of the students, agreed to be screened. A
monthly average of 350 individuals, totaling
13,670 over the period (including probands and
relatives) were investigated in the programs. A
mean hemoglobin disorder prevalence of 4.7%
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was observed. Table 1 shows the frequency of
hereditary hemoglobin defects diagnosed in
the population samples.
Fourteen cases of chronic hemolytic ane-
mia (9 SS, 3 SC, 1 TT, and 1 CC) at ages from
four months to 35 years (X = 9.8 years) are of
special interest. Of the 630 heterozygotes, 378
were 15 years old or older, and of these, 228
(60%) agreed to receive genetic counseling.
Rate of acceptance of genetic counseling was
64.5% among women and 50.6% among men
( c 2 = 4.29; 0.02<p<0.05).
Twenty at-risk heterozygous couples (11 AS
x AS, 5 AS x AC, 2 AT x AT, 1 AC x AC, and 1 AS x
AT) were diagnosed. These couples had not re-
ceived previous genetic counseling, and nine
of them had a child with a clinically significant
hemoglobinopathy (7 SS, 1 SC, and 1 CC).
As additional information from this study,
four cases of persistent hereditary fetal hemo-
globin and two cases of Camperdown hemo-
globin were diagnosed by DNA analysis among
the pregnant women.
Table 2 shows some program efficiency in-
dicators.
Discussion
The first and perhaps most important aspect to
emphasize when discussing this study is the
high receptivity of a Brazilian community to
health programs offered on a voluntary, non-
coercive basis, as recommended by the São
Paulo State Medical Code of Ethics (CREMESP,
1988). Programs showed satisfactory efficiency
indicators, expressed by the significant propor-
tion of tests performed. However, the program
focusing on pregnant women was more effec-
tive than those screening blood donors and
students, as evaluated by the percentage of rel-
atives who volunteered for tests. The group of
symptomatic individuals referred by physi-
cians from the community was particularly
useful for diagnosis of hemoglobin defects.
This strategy thus deserves special attention in
community-based programs.
Table 1
Diagnosed hemoglobinopathies in the population samples (in percentages).
Population samples Hemoglobin defects
AS AT AC SS TT SC CC Total
Pregnant women (n = 2,209) 2.4 0.8 0.4 3.6
Husbands* (n = 45) 2.2 2.2 4.4 8.8
Newborn children* (n = 60) 33.3 11.7 3.3 1.7 50.0
Other children* (n = 85) 37.6 5.9 9.4 1.2 1.2 55.3
Siblings* (n = 260) 28.5 13.0 5.4 0.8 47.7
Blood donors (n = 9,196) 1.0 0.3 1.3
Spouses* (n = 30) 10.0 3.3 13.3
Children* (n = 61) 45.9 1.6 3.3 50.8
Students (n = 1,118) 0.6 1.2 0.2 2.0
Parents and siblings* (n = 53) 7.5 37.7 45.2
Sub-Total (n = 13,117) 2.4 0.8 0.5 0.03 0.01 0.01 3.74
Individuals referred by physicians 11.2 13.4 3.0 0.9 0.5 29.0
and relatives (n = 553)
Total (n = 13,670) 2.7 1.3 0.6 0.07 0.01 0.02 0.01 4.71
AS = sickle cell trait; AT = b -thalassemia trait; AC = hemoglobin C trait; SS = sickle cell anemia; 
TT = b -thalassemia major; SC = hemoglobin SC disease; CC = hemoglobin C disease.
* Relatives of heterozygotes.
Table 2
Program efficiency indicators.
Indicator Pregnant women Blood donors Students
Compliance (%) 100 100 54
Partner testing* (%) 56 33 –
Parent testing* (%) – – 65
Testing of children and/or 90 60 65
other relatives* (%)
Mean number of individuals 5.6 0.76 2.4
examined for each heterozygote 
* Relatives of heterozygotes.
RAMALHO, A. S. et al.594
Cad. Saúde Pública, Rio de Janeiro, 15(3):591-595, jul-set, 1999
References
BOWMAN, J., 1991. Prenatal screening for hemoglo-
binopathies. American Journal of Human Genet-
ics, 48:433-438.
CREMESP (Conselho Regional de Medicina do Esta-
do de São Paulo), 1988. Código de Ética Médica.
São Paulo: CREMESP.
GRANDA, H.; GISPERT, S.; DORTICOS, A.; MARTIN,
M.; CUADRAS, Y.; CALVO, M.; MARTINEZ, G.; ZA-
YAS, M. A.; OLIVA, J. A. & HEREDERO, L., 1991.
Cuban programme for prevention of sickle cell
disease. Lancet, 337:152-153.
KESSLER, S., 1989. Psychological aspects of genetic
counseling. A critical review of literature dealing
with education and reproduction. American Jour-
nal of Medical Genetics, 34:340-353.
Prenatal screening for hemoglobinopathies
has several pragmatic advantages (Rowley et
al., 1991). Pregnant women already have rou-
tine blood tests in the prenatal period, and
during pregnancy women are more aware of
their own health and that of their children. Pre-
natal screening for hemoglobinopathies in oth-
er countries, such as the United States (Rowley
et al., 1991), Cuba (Granda et al., 1991), Greece
(Loukopoulos, 1985), Canada (Scriver et al.,
1984), and Italy (Tentori & Marinucci, 1983) al-
so provided satisfactory results. However, these
programs conducted in the Northern Hemi-
sphere included the possibility of fetal diagno-
sis and optional therapeutic abortion in their
objectives. The advantages and disadvantages
of prenatal screening for hemoglobinopathies
have been thoroughly discussed by Bowman
(1991) and Loader et al. (1991)
Population screening is extremely valuable
for initiating early treatment, and in this case
families may become fully prepared for the
management of babies with serious hemoglo-
binopathies. Some societies offer prenatal di-
agnosis, but even if this is not the case, in Brazil
there are enormous advantages to such educa-
tional programs.
Acceptance of optional genetic counseling
by heterozygotes (60%) was considered satis-
factory and was significantly higher amongst
women. However, it was lower than that ob-
served by Rowley et al. (1991) in the Rochester
program in the United States (69%) ( c 2 = 4.94;
0.02<p<0.05). Since the genetic counseling of-
fered in the Campinas programs had essential-
ly educational objectives, a complementary in-
struction leaflet was given to heterozygotes, ex-
plaining their hemoglobin defect in detail. Ac-
cording to Kessler (1989), genetic counseling
programs are more efficient when the goals are
educational rather than eugenic. The most
gratifying short-term result of the programs in
Campinas was the increased community aware-
ness concerning hemoglobin disorders.
From the clinical point of view, another
gratifying result was the diagnosis and treat-
ment of 14 cases of chronic hemolytic anemia
and 178 b -thalassemia trait carriers, many with
hypochromic and microcytic anemia. Although
hemoglobinopathies are not curable, they are
treatable, resulting in improved quality of life
for patients. For example, such simple mea-
sures as vaccination and prophylactic admin-
istration of penicillin to children with sickle
cell syndromes increase their life expectancy
(Vichinsky et al., 1988; Wong et al., 1992).
Neonatal screening is thus an option for early
treatment of hemoglobinopathies.
Finally, the programs’ cost/benefit relation-
ship deserves to be highlighted. At a cost of on-
ly US$1.10 per person the programs were able
to screen of a large number of people and
achieve increased community awareness con-
cerning hemoglobin disorders.
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